Level of Instruction: Intermediate
Intended Audience: Medical laboratory scientists, medical laboratory technicians, pathology residents, MLS students, and other health care personnel who have an interest in this subject matter.
Author information: Nancy Liu-Sullivan, PhD is the academic advisor of the Medical Technology program at the College of Staten Island (CSI), a senior college of the City University of New York. In addition to teaching and being the course leader, Dr. Liu-Sullivan also runs a research laboratory that focuses on identifying drug targets as novel chemotherapeutics for brain cancer using 3-D cell culture system. Before joining the biology faculty at the College of Staten Island, Dr. Liu-Sullivan worked as a senior research scientist at MSKCC, with more than a decade of cancer research expertise.
Reviewer information: Ralph Garippa, PhD, is Director of Gene Editing and RNAi Core Facility at Memorial Sloan Kettering Cancer Center, with more than two decades of drug discovery expertise and leadership. He is the former Head of Cell-Based High Throughput Screening and Microscopic Imaging-based High Content Screening at Hoffmann-La Roche’s Nutley NJ facility. His previous academic partners included Harvard University, Massachusetts General Hospital, and The Hebrew University in Jerusalem, Israel. Dr. Garippa holds a Ph.D. in Pharmacology from Columbia University and a B.A. degree in Biology from Fairleigh Dickinson University.
Reviewer information: Kevin F. Foley, PhD, DABCC, MT, is the director of clinical pathology for the Kaiser Permanente Northwest region. He also teaches clinical chemistry at Oregon Health Sciences University. Dr. Foley earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina. He received a PhD in clinical pharmacology and toxicology from Brody School of Medicine, Greenville, NC. He has been working in laboratory medicine for over 15 years, starting his career as a medical technologist.